Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from SynAct Pharma AB ( (SE:SYNACT) ) is now available.
SynAct Pharma has completed dosing of the last patient in its Phase 2b ADVANCE study of resomelagon in newly diagnosed rheumatoid arthritis patients starting first-line methotrexate therapy. The trial, conducted at more than 30 sites and involving 246 patients with elevated inflammation and severe symptoms, is testing multiple oral doses of the melanocortin agonist over 12 weeks in a randomized, double-blind, placebo-controlled design.
The database lock process is now under way, after which statistical analyses will be performed ahead of topline data expected in June 2026, in line with earlier guidance. Positive results could validate SynAct’s resolution-focused approach as a potentially safer alternative or addition to existing immunosuppressive regimens, support Phase 3 readiness, and strengthen the company’s strategic position in the large and growing rheumatoid arthritis market.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm that focuses on resolving inflammation by selectively activating the melanocortin system. The company is developing a portfolio of oral and injectable melanocortin agonists designed to induce anti-inflammatory and inflammation-resolution activity, with the goal of restoring immune balance for patients with inflammatory diseases.
Average Trading Volume: 195,935
Technical Sentiment Signal: Sell
Current Market Cap: SEK906.6M
Learn more about SYNACT stock on TipRanks’ Stock Analysis page.